NeoGenomics, Inc. (NEO) Stock Score, Valuation & Financial Research
NeoGenomics, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for NEO
NeoGenomics, Inc. currently has a Wall Street Score of 28/100. The stored market price is $18.89. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What NeoGenomics, Inc. does
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localizat
NEO financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $18.89
- Market capitalization:
- $485.4M
- Revenue:
- $746.0M
- Net income:
- $-99.2M
- Free cash flow:
- $-21.8M
- Cash:
- $146.1M
- Total debt:
- $408.5M
- EPS:
- -4.20
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 31/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-21.8M, showing cash burn in the current stored period.
- The balance sheet shows $146.1M of cash versus $408.5M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NEO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.